Company: TAK
Filing Date: 2025-06-27
Form Type: 424B2
Source: 0001628280-25-033198
Chunk: 8

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-27
Form: 424B2
Chunk 8
---
&D investments in PDT. We focus on developing innovative medicines that make a difference in people’s lives by advancing the frontier of new treatment options and leveraging our collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. We focus on high unmet medical needs, both in rare and more prevalent conditions, to deliver high-quality medicines to patients and communities as quickly as possible. We have a presence in approximately 80 countries and regions, a network of manufacturing sites around the world, primarily in the United States, Europe, Japan, and Singapore and major research centers in Japan and the United States. Commercially, we have a very significant presence in the United States, Japan, and Europe as well as a fast-growing business in China. We have also accelerated our focus on data, digital and technology to make our business operations more effective and efficient, increase innovation and better serve our stakeholders.

See “Item 4.B. Information on the Company—Business Overview” in our annual report for the fiscal year ended March 31, 2025 on Form 20-F, which is incorporated herein by reference.

The address of TPC’s registered head office is 1-1 Nihonbashi Honcho 2-chome, Chuo-ku, Tokyo 103-8668, Japan. TPC’s telephone number is +81-3-3278-2306, and Takeda’s internet site is http://www.takeda.com. The information on Takeda’s internet site is not incorporated by reference herein and does not form a part of this prospectus supplement.

#### TAKEDA U.S. FINANCING, INC.
TUSFI is a Delaware corporation and the issuer of the Notes. It is TPC’s indirect wholly-owned finance subsidiary and issues debt securities for the benefit of Takeda.

The expectations described above are forward-looking statements based on Takeda’s assumptions and beliefs as of the date of this prospectus supplement and are subject to the qualifications set forth under “Cautionary Statement Regarding Forward-Looking Statements.” Takeda’s actual results may vary due to factors such as those discussed under “Item 3. Key Information—D. Risk Factors” of Takeda’s most recent annual report on Form 20-F filed with the SEC and in the “Risk Factors” section beginning on page S- 7 of this prospectus supplement or unanticipated events and circumstances.

<div align='center'>S-1</div>

### SUMMARY RISK FACTORS